DYADIC INTERNATIONAL

Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

27 Oct 2022 15:30:00 By Nasdaq GlobeNewswire

Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

27 Oct 2022 08:04:29 By Nasdaq GlobeNewswire

Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential

04 Oct 2022 07:45:06 By Nasdaq GlobeNewswire

Dyadic Updates Market on Recent Scientific Achievements

13 Sep 2022 07:00:02 By Nasdaq GlobeNewswire

Dyadic to Present at Upcoming Industry and Investor Events in September

08 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments

10 Aug 2022 15:00:00 By Nasdaq GlobeNewswire

Dyadic to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

27 Jul 2022 15:30:00 By Nasdaq GlobeNewswire

Dyadic to Participate in Bio-Manufacturing Innovation Summit and NIIMBL National Meeting

05 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Dyadic to Participate in Three Upcoming Industry Events

09 Jun 2022 08:09:20 By Nasdaq GlobeNewswire

Dyadic to Present at 2022 Jefferies Healthcare Conference

02 Jun 2022 08:27:39 By Nasdaq GlobeNewswire

Dyadic to Present at H.C. Wainwright Global Investment Conference

20 May 2022 07:30:00 By Nasdaq GlobeNewswire

Dyadic Reports First Quarter 2022 Financial Results and Highlights Recent Company Developments

12 May 2022 15:00:00 By Nasdaq GlobeNewswire

Dyadic Announces Research, License and Collaboration for the Manufacture of Animal Free Ingredients

11 May 2022 07:30:00 By Nasdaq GlobeNewswire

Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”

09 May 2022 07:30:00 By Nasdaq GlobeNewswire

Dyadic to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

28 Apr 2022 15:30:00 By Nasdaq GlobeNewswire

Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production Platform

13 Apr 2022 07:52:30 By Nasdaq GlobeNewswire

Dyadic International to Present at Upcoming Scientific Medical Meetings

04 Apr 2022 07:30:00 By Nasdaq GlobeNewswire

Dyadic Reports 2021 Year End Results and Recent Company Progress

29 Mar 2022 15:00:00 By Nasdaq GlobeNewswire

Dyadic to Report 2021 Year-End Financial Results on Tuesday, March 29, 2022

15 Mar 2022 15:30:00 By Nasdaq GlobeNewswire

Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine

10 Feb 2022 07:30:00 By Nasdaq GlobeNewswire